title: bax-deficiency promotes drug resistance and oncogenic transformation by attenuating p53-dependent apoptosis.
abstract: Inactivation of p53-dependent apoptosis promotes oncogenic transformation, tumor development, and resistance to many cytotoxic anticancer agents. p53 can transcriptionally activate bax, a bcl-2 family member that promotes apoptosis. To determine whether bax is required for p53-dependent apoptosis, the effects of bax deficiency were examined in primary fibroblasts expressing the E1A oncogene, a setting where apoptosis is dependent on endogenous p53. We demonstrate that bax can function as an effector of p53 in chemotherapy-induced apoptosis and contributes to a p53 pathway to suppress oncogenic transformation. Furthermore, we show that additional p53 effectors participate in these processes. These p53-controlled factors act synergistically with Bax to promote a full apoptotic response, and their action is suppressed by the Bcl-2 and E1B 19K oncoproteins. These studies demonstrate that Bax is a determinant of p53-dependent chemosensitivity and illustrate how p53 can promote apoptosis by coordinating the activities of multiple effectors.
authors.affiliation: Cold Spring Harbor Laboratory, New York 11724, USA.
authors.forename: M E
authors.initials: ME
authors.lastname: McCurrach
authors.forename: T M
authors.initials: TM
authors.lastname: Connor
authors.forename: C M
authors.initials: CM
authors.lastname: Knudson
authors.forename: S J
authors.initials: SJ
authors.lastname: Korsmeyer
authors.forename: S W
authors.initials: SW
authors.lastname: Lowe
mesh_terms: D000818:Animals; D017209:Apoptosis; D002470:Cell Survival / Q000187:drug effects; D002471:Cell Transformation, Neoplastic; D002478:Cells, Cultured; D002945:Cisplatin / Q000494:pharmacology; D003433:Crosses, Genetic; D004317:Doxorubicin / Q000494:pharmacology; D004351:Drug Resistance / Q000235:genetics*; D004622:Embryo, Mammalian; D005047:Etoposide / Q000494:pharmacology; D005347:Fibroblasts; D016158:Genes, p53; D051379:Mice; D018345:Mice, Knockout; D011518:Proto-Oncogene Proteins / Q000172:deficiency* / Q000235:genetics; D019253:Proto-Oncogene Proteins c-bcl-2; D012333:RNA, Messenger / Q000096:biosynthesis; D011995:Recombination, Genetic; D014158:Transcription, Genetic; D016159:Tumor Suppressor Protein p53 / Q000096:biosynthesis / Q000378:metabolism; D051028:bcl-2-Associated X Protein
chemical_list: C494827:Bax protein, mouse; D011518:Proto-Oncogene Proteins; D019253:Proto-Oncogene Proteins c-bcl-2; D012333:RNA, Messenger; D016159:Tumor Suppressor Protein p53; D051028:bcl-2-Associated X Protein; D005047:Etoposide; D004317:Doxorubicin; D002945:Cisplatin